Last reviewed · How we verify
IOV-2001
At a glance
| Generic name | IOV-2001 |
|---|---|
| Also known as | Autologous PBL |
| Sponsor | Iovance Biotherapeutics, Inc. |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Study of Autologous Peripheral Blood Lymphocytes in the Treatment of Patients With CLL or SLL (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- IOV-2001 CI brief — competitive landscape report
- IOV-2001 updates RSS · CI watch RSS
- Iovance Biotherapeutics, Inc. portfolio CI